A business venture between Gumlink A/S and Tab Labs Inc. has the leading gum developers has both companies staged for a growing nutraceutical gum market.
A business venture between two of the world’s leading gum developers has both companies staged for a growing nutraceutical gum market.
With manufacturing technologies, functional ingredients in chewing gum are becoming less of a pipe dream and more of a reality. Today, Gumlink A/S (Vejle, Denmark) announced that the European business-to-business developer of chewing gum has acquired 50% stake in Tab Labs Inc. (Vancouver), a North American developer of chewing gum technologies. This joining of forces is expected to speed up progress in the nutraceutical chewing gum market, namely related to probiotics.
At the same time, Dr. Chris Chilcott, known for his part in developing oral probiotic strains Blis K-12 and Blis M-18, is joining Tab Labs to head the company’s new Nutraceutical Innovation Center.
Gumlink CEO Soren Birn sums up his expectations of the new business venture:
This move makes perfect sense for us, as it will provide us with a nutraceutical manufacturing and distribution platform in North America and provide access to novel technologies that, when combined with our own proprietary gum technologies, will enable us to offer the most potent nutraceutical chewing gum assortment. Furthermore, Gumlink is now following our strategic pathway to maintain and further build our position as the world’s leading nutraceutical gum developer and manufacturer.